Company news

Exicure, Inc. (NASDAQ:XCUR) news

Exicure, Inc. news releases on 6ix. Latest, Sep 16, 2026: Exicure Receives Nasdaq Extension to Regain Compliance with Stockholders’ Equity Requirement

Exicure, Inc. (NASDAQ:XCUR) news

Press releases & updates

Exicure Receives Nasdaq Extension to Regain Compliance with Stockholders’ Equity Requirement

Exicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity Issuance

Exicure Announces Board and Committee Changes

Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders’ Equity Requirement

Exicure Announces Receipt of Nasdaq Delinquency Notice and Filing of Form 10-Q

Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)

Exicure, Inc. Reports Full Year 2025 Financial Results

Exicure Announces Publication in Annals of Hematology Highlighting Rapid Stem Cell Mobilization with Burixafor in Patients with Multiple Myeloma and Lymphoma Undergoing Transplant

Exicure to Present Data from Burixafor Phase 2 Trial at the 2026 Tandem Meetings

Exicure Presents Positive Topline Phase 2 Data for Burixafor in Multiple Myeloma at 2025 ASH Annual Meeting

Exicure, Inc. Reports Third Quarter 2025 Financial Results

New Burixafor Clinical Data to be Presented as an Oral Presentation at the 2025 ASH Annual Meeting

Exicure Highlights Recent Achievements and Near-term Strategic Priorities

Exicure, Inc. Reports Second Quarter 2025 Financial Results

Exicure, Inc. (Nasdaq: XCUR) Regains Compliance with Nasdaq Filing Requirements

Exicure Completes the Last Patient, Last Visit in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant

Exicure, Inc. Reports First Quarter 2025 Financial Results

Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q

Exicure Completes Patient Enrollment in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant

Exicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study of GPC-100 in Multiple Myeloma

Exicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML)

Exicure, Inc. Reports Full Year 2024 Financial Results

Exicure, Inc. (Nasdaq: XCUR) Announces Issuance of New Patent in Australia

CORRECTING and REPLACING Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.

Exicure, Inc. Partners with GPCR Therapeutics to Fuel New Growth in Biotech

Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes

CORRECTING and REPLACING Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes

Exicure, Inc. Enters into Purchase Agreements for $1.3 Million and $8.7 Million Equity Financing and Reports Third Quarter 2024 Financial Results

Exicure, Inc. Receives Extension from Nasdaq Hearings Panel

Exicure, Inc. Announces Proposed Settlement of Securities Class Action Litigation

Exicure, Inc. Announces 1-for-5 Reverse Stock Split

Exicure, Inc. Announces Adjournment of Special Meeting and Information for Reconvened Special Meeting

Exicure, Inc. Reports Second Quarter 2024 Financial Results

Exicure, Inc. Recruits Head of Corporate Development and Bioinformatics

Exicure, Inc. Receives Positive Listing Determination from Nasdaq

Exicure, Inc. Reports First Quarter 2024 Financial Results

Exicure, Inc. Reports Full Year 2023 Financial Results

Exicure, Inc. Received Nasdaq Notice of a Delisting Determination

Exicure, Inc. Reports Third Quarter 2023 Financial Results

Exicure, Inc. and Bluejay Therapeutics Inc. Enter into a Patent License Agreement to Develop Cavrotolimod for the Treatment of Hepatitis

Exicure, Inc. Announces Appointment of New CEO and CFO and Changes to Board of Directors

Exicure, Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Exicure, Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Update

Exicure, Inc. Announces Support of CEO in its Ongoing Exploration of Strategic Alternatives

Exicure, Inc. Announces Investment in Korean SNS Platform Cyworld

Exicure, Inc. Reports Full Year 2022 Financial Results and Provides Corporate Update

Exicure, Inc. Announces Closing of Private Placement Transaction with CBI USA, Inc. and Changes to the Board of Directors

Exicure, Inc. Announces Termination of AbbVie and Ipsen Collaboration Agreements

Exicure, Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Exicure, Inc. Enters Into Definitive Agreement With CBI USA, Inc. for $5.4 Million Equity Financing and Announces Implementation of Strategic Measure to Reduce Cash Burn and Prioritize Strategic Alternatives